HIT Consultant November 5, 2024
What You Should Know:
– PrognomiQ, a healthcare company pioneering multi-omics approaches to disease detection, has secured $34M in Series D funding led by Seer, Inc., with participation from a new strategic investor and existing investors including Catalio Capital Management, aMoon, Invus and Bruker.
– The funding brings PrognomiQ’s total funding to more than $135M and will accelerate the development of PrognomiQ’s early detection test for lung cancer.
Enhancing Lung Cancer Detection with Multi-Omics
Lung cancer is a leading cause of cancer-related deaths worldwide. Early detection is crucial for improving survival rates, but current screening methods have limitations. PrognomiQ’s multi-omics test addresses this unmet need by providing a more accurate and accessible screening option.PrognomiQ is developing a groundbreaking...
Today's Sponsors
Today's Sponsor